Research Article

TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy

Table 1

Baseline demographic and clinical characteristics of the 383 rheumatoid arthritis patients treated with anti-TNF drugs.

TNF inhibitor
 Adalimumab79 (20.6)
 Etanercept139 (36.3)
 Golimumab10 (2.6)
 Infliximab155 (40.5)
Age (years)52.5 (12.2)
Disease duration (years)10.7 (8.9)
Female 343 (89.5)
Rheumatoid factor 290 (75.7)
ACPA 278 (72.6)
Extra-articular manifestations91 (23.7)
Smoking-ever ()71 (19.3)
Education (years) 7.1 (4.6)
DMARDs ()346 (91.8)
MTX () 310 (82.2)
Corticosteroids ()277 (73.5)
DAS28 ESR5.77 (1.1)
Physician global assessment (mm)56.1 (16.5)
Health Assessment Questionnaire1.45 (0.58)

Values shown are means (SD) or (%).
TNF: tumor necrosis factor; ACPA: anticitrullinated peptides antibodies; DMARDs: disease modifying antirheumatic drugs; MTX: methotrexate; DAS: disease activity score; ESR: erythrocyte sedimentation rate.